| 000 | 01220 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250513234811.0 | ||
| 264 | 0 | _c20010607 | |
| 008 | 200106s 0 0 eng d | ||
| 022 | _a1527-9995 | ||
| 024 | 7 |
_a10.1016/s0090-4295(00)00978-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKeegan, P | |
| 245 | 0 | 0 |
_aEarly clinical trials of chemopreventive and biologic agents: Designs, populations, and endpoints. _h[electronic resource] |
| 260 |
_bUrology _cApr 2001 |
||
| 300 |
_a216-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAnticarcinogenic Agents _xpharmacology |
| 650 | 0 | 4 |
_aClinical Trials as Topic _xmethods |
| 650 | 0 | 4 | _aClinical Trials, Phase I as Topic |
| 650 | 0 | 4 | _aClinical Trials, Phase II as Topic |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aDrug Screening Assays, Antitumor _xmethods |
| 650 | 0 | 4 |
_aFlurbiprofen _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aProstatic Neoplasms _xprevention & control |
| 650 | 0 | 4 | _aResearch Design |
| 700 | 1 | _aLoughman, B E | |
| 773 | 0 |
_tUrology _gvol. 57 _gno. 4 Suppl 1 _gp. 216-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0090-4295(00)00978-x _zAvailable from publisher's website |
| 999 |
_c11230790 _d11230790 |
||